Literature DB >> 21838851

Evaluation of ethyl glucuronide immunoassay urinalysis in five alcohol-dependent outpatients.

Michael G McDonell, Debra Srebnik, Frank Angelo, Andrea M Sugar, Donelle Howell, Christina Rainey, John Roll, Robert Short, Richard Ries.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21838851      PMCID： PMC3156614          DOI： 10.1111/j.1521-0391.2011.00157.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN： 1055-0496


× No keyword cloud information.
  4 in total

1.  Use of case manager ratings and weekly urine toxicology tests among outpatients with dual diagnoses.

Authors:  Richard K Ries; Dennis G Dyck; Robert Short; Debra Srebnik; Mark Snowden; Katherine Anne Comtois
Journal:  Psychiatr Serv       Date:  2002-06       Impact factor: 3.084

2.  Comparison of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions.

Authors:  S T Chermack; J Roll; M Reilly; L Davis; U Kilaru; J Grabowski
Journal:  Drug Alcohol Depend       Date:  2000-04-01       Impact factor: 4.492

3.  Ethyl glucuronide: a biomarker to identify alcohol use by health professionals recovering from substance use disorders.

Authors:  Gregory E Skipper; Wolfgang Weinmann; Annette Thierauf; Patrick Schaefer; Gerhard Wiesbeck; John P Allen; Michael Miller; Friedrich Martin Wurst
Journal:  Alcohol Alcohol       Date:  2004-08-02       Impact factor: 2.826

4.  Evaluation of a new immunoassay for urinary ethyl glucuronide testing.

Authors:  Michael Böttcher; Olof Beck; Anders Helander
Journal:  Alcohol Alcohol       Date:  2007-10-17       Impact factor: 2.826
  4 in total
  7 in total

1.  Voucher-based reinforcement for alcohol abstinence using the ethyl-glucuronide alcohol biomarker.

Authors:  Michael G McDonell; Donelle N Howell; Sterling McPherson; Jennifer M Cameron; Debra Srebnik; John M Roll; Richard K Ries
Journal:  J Appl Behav Anal       Date:  2012

2.  Use of continuous transdermal alcohol monitoring during a contingency management procedure to reduce excessive alcohol use.

Authors:  Donald M Dougherty; Nathalie Hill-Kapturczak; Yuanyuan Liang; Tara E Karns; Sharon E Cates; Sarah L Lake; Jillian Mullen; John D Roache
Journal:  Drug Alcohol Depend       Date:  2014-07-11       Impact factor: 4.492

3.  Pilot investigation: randomized-controlled analog trial for alcohol and tobacco smoking co-addiction using contingency management.

Authors:  Michael F Orr; Crystal Lederhos Smith; Myles Finlay; Samantha C Martin; Olivia Brooks; Oladunni A Oluwoye; Emily Leickly; Michael McDonell; Ekaterina Burduli; Celestina Barbosa-Leiker; Matt Layton; John M Roll; Sterling M McPherson
Journal:  Behav Pharmacol       Date:  2018-08       Impact factor: 2.293

4.  High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry.

Authors:  Emily Leickly; Michael G McDonell; Roger Vilardaga; Frank A Angelo; Jessica M Lowe; Sterling McPherson; Debra Srebnik; John M Roll; Richard K Ries
Journal:  Am J Drug Alcohol Abuse       Date:  2015-02-19       Impact factor: 3.829

5.  A culturally-tailored behavioral intervention trial for alcohol use disorders in three American Indian communities: Rationale, design, and methods.

Authors:  Michael G McDonell; Jenny R Nepom; Emily Leickly; Astrid Suchy-Dicey; Kait Hirchak; Abigail Echo-Hawk; Stephen M Schwartz; Darren Calhoun; Dennis Donovan; John Roll; Richard Ries; Dedra Buchwald
Journal:  Contemp Clin Trials       Date:  2015-12-17       Impact factor: 2.226

Review 6.  Biomolecules and Biomarkers Used in Diagnosis of Alcohol Drinking and in Monitoring Therapeutic Interventions.

Authors:  Radu M Nanau; Manuela G Neuman
Journal:  Biomolecules       Date:  2015-06-29

7.  A wearable biochemical sensor for monitoring alcohol consumption lifestyle through Ethyl glucuronide (EtG) detection in human sweat.

Authors:  Anjan Panneer Selvam; Sriram Muthukumar; Vikramshankar Kamakoti; Shalini Prasad
Journal:  Sci Rep       Date:  2016-03-21       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.